We present evidence that HDAC inhibition increases cisplatin efficacy in eliminating cancer cells via the repression of HDAC1-Sp5, and the subsequent de-repression of proliferation inhibitor p21 manifests as inhibition of tumor clusters. Here, HDAC9 is linked to cancer.